1-20 of 21
Harry Erba
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data
Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Clinical Trials & Observations
Wendy Stock, Selina M. Luger, Anjali S. Advani, Jun Yin, Richard C. Harvey, Charles G. Mullighan, Cheryl L. Willman, Noreen Fulton, Kristina M. Laumann, Greg Malnassy, Elisabeth Paietta, Edy Parker, Susan Geyer, Krzysztof Mrózek, Clara D. Bloomfield, Ben Sanford, Guido Marcucci, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Jeffrey A. Bogart, John C. Grecula, Frederick R. Appelbaum, Harry Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson
Journal: Blood
Blood (2019) 133 (14): 1548–1559.
https://doi.org/10.1182/blood-2018-10-881961
Published: 2019
Includes: Supplemental data
Journal Articles

Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Clinical Trials & Observations
Simon Mantha, Debra A. Goldman, Sean M. Devlin, Ju-Whei Lee, Diana Zannino, Marnie Collins, Dan Douer, Harry J. Iland, Mark R. Litzow, Eytan M. Stein, Frederick R. Appelbaum, Richard A. Larson, Richard Stone, Bayard L. Powell, Susan Geyer, Kristina Laumann, Jacob M. Rowe, Harry Erba, Steven Coutre, Megan Othus, Jae H. Park, Peter H. Wiernik, Martin S. Tallman
Journal: Blood
Blood (2017) 129 (13): 1763–1767.
https://doi.org/10.1182/blood-2016-10-747170
Published: 2017
Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Wendy Stock, MD, Selina M. Luger, MD, Anjali S. Advani, MD, Susan Geyer, PhD, Richard C. Harvey, PhD, Charles G. Mullighan, MBBS, MSc, MD, Cheryl L. Willman, MD, Greg Malnassy, B.S., Edy Parker, Kristina M Laumann, BA, Ben Sanford, Guido Marcucci, MD, Elisabeth M. Paietta, PhD, Michaela Liedtke, MD, David F. Claxton, MD, Matthew C. Foster, MD, Frederick R. Appelbaum, MD, Harry Erba, Mark R. Litzow, MD, Martin S. Tallman, MD, Richard M. Stone, MD, Richard A. Larson
Journal: Blood
Blood (2014) 124 (21): 796.
https://doi.org/10.1182/blood.V124.21.796.796
Published: 2014
Journal Articles

Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience

Racquel Innis-Shelton, MD, Donna Salzman, MD, Antonio Di Stasi, MD, Lawrence S. Lamb, PhD, Melissa Gazi, Lisa Williams, RN, Luciano J Costa, MD PhD, Harry Erba, Shin Mineishi, MD, Ayman Saad, MD
Journal: Blood
Blood (2014) 124 (21): 3911.
https://doi.org/10.1182/blood.V124.21.3911.3911
Published: 2014
Journal Articles

Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia

Brief Report
Meng Li, Roxane Collins, Yuchen Jiao, Peter Ouillette, Dale Bixby, Harry Erba, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Sami N. Malek
Journal: Blood
Blood (2011) 118 (22): 5914–5917.
https://doi.org/10.1182/blood-2011-05-356204
Published: 2011
Includes: Supplemental data
Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Clinical Trials & Observations
John Magenau, Hiromi Tobai, Attaphol Pawarode, Thomas Braun, Edward Peres, Pavan Reddy, Carrie Kitko, Sung Choi, Gregory Yanik, David Frame, Andrew Harris, Harry Erba, Lisa Kujawski, Kojo Elenitoba-Johnson, Jennifer Sanks, Dawn Jones, Sophie Paczesny, James Ferrara, John Levine, Shin Mineishi
Journal: Blood
Blood (2011) 118 (15): 4258–4264.
https://doi.org/10.1182/blood-2011-06-358010
Published: 2011
Includes: Supplemental data
Journal Articles

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Clinical Trials & Observations
Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia A. Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W. Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith
Journal: Blood
Blood (2011) 117 (12): 3294–3301.
https://doi.org/10.1182/blood-2010-08-301796
Published: 2011
Journal Articles

Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia

Clinical Trials & Observations
Brian Parkin, Harry Erba, Peter Ouillette, Diane Roulston, Anjali Purkayastha, Judith Karp, Moshe Talpaz, Lisa Kujawski, Sajid Shakhan, Cheng Li, Kerby Shedden, Sami N. Malek
Journal: Blood
Blood (2010) 116 (23): 4958–4967.
https://doi.org/10.1182/blood-2010-01-266999
Published: 2010
Includes: Supplemental data
Journal Articles

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

Jianting Long, Brian Parkin, Peter Ouillette, Dale Bixby, Kerby Shedden, Harry Erba, Shaomeng Wang, Sami N. Malek
Journal: Blood
Blood (2010) 116 (1): 71–80.
https://doi.org/10.1182/blood-2010-01-261628
Published: 2010
Includes: Supplemental data
Journal Articles

Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse.

Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R Baer, Alexander Perl, Steven Coutre, MD, Harry Erba, MD, Robert K Stuart, Michele Baccarani, MD, Larry D. Cripe, Martin S. Tallman, MD, Giovanna Meloni, Lucy A Godley, Amelia A Langston, MD, PhD, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, M.D., Dan Douer, Wieslaw W. Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M Bensen-Kennedy, Donald Small, B. Douglas Smith
Journal: Blood
Blood (2009) 114 (22): 788.
https://doi.org/10.1182/blood.V114.22.788.788
Published: 2009
Journal Articles

Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 Randomized Trial Comparing the Addition of Gemtuzumab Ozogamicin to Standard Induction Therapy Versus Standard Induction Therapy Followed by a Second Randomization to Post-Consolidation Gemtuzumab Ozogamicin Versus No Additional Therapy for Previously Untreated Acute Myeloid Leukemia.

Stephen Petersdorf, MD, Kenneth Kopecky, PhD, Robert K Stuart, MD, Richard A. Larson, MD, Thomas J. Nevill, MD, FRCPC, Leif Stenke, MD, PhD, Marilyn L. Slovak, PhD, Martin S. Tallman, MD, Cheryl L. Willman, MD, Harry Erba, MD, Frederick R Appelbaum
Journal: Blood
Blood (2009) 114 (22): 790.
https://doi.org/10.1182/blood.V114.22.790.790
Published: 2009
Journal Articles

Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia.

Jianting Long, MD, Peter Ouillette, Brian Parkin, Harry Erba, Shaomeng Wang, Sami Malek, MD
Journal: Blood
Blood (2008) 112 (11): 1607.
https://doi.org/10.1182/blood.V112.11.1607.1607
Published: 2008
Journal Articles

Comprehensive Ultra High Resolution Analysis of Copy Number and Allele Status Including Novel Microdeletions Spanning NF1 in Acute Myelogenous Leukemia

Sami Malek, MD, Peter Ouillette, Whitney Wright, Amanda Dressel, Judy Karp, Paula Bockenstedt, Ammar Al-Zoubi, Moshe Talpaz, Lisa Kujawski, Kerby Shedden, Sajid Shakhan, Cheng Li, Harry Erba, Brian Parkin
Journal: Blood
Blood (2008) 112 (11): 3107.
https://doi.org/10.1182/blood.V112.11.3107.3107
Published: 2008
Journal Articles

Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

Lisa Kujawski, Peter Ouillette, Harry Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, Sami N. Malek
Journal: Blood
Blood (2008) 112 (5): 1993–2003.
https://doi.org/10.1182/blood-2007-07-099432
Published: 2008
Includes: Supplemental data
Journal Articles

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia

Chris Saddler, Peter Ouillette, Lisa Kujawski, Sanjeev Shangary, Moshe Talpaz, Mark Kaminski, Harry Erba, Kerby Shedden, Shaomeng Wang, Sami N. Malek
Journal: Blood
Blood (2008) 111 (3): 1584–1593.
https://doi.org/10.1182/blood-2007-09-112698
Published: 2008
Includes: Supplemental data
Journal Articles

Genomic Complexity Identifies Patients with Agressive Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Harry Erba, MD, PhD, Chris Saddler, BS, Andrzej Jakubowiak, MD, Mark Kaminski, MD, Kerby Shedden, PhD, Lisa Kujawski, MD
Journal: Blood
Blood (2007) 110 (11): 489.
https://doi.org/10.1182/blood.V110.11.489.489
Published: 2007
Journal Articles

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.

Sami N. Malek, MD, Peter Ouillette, MT, ASCP, Lisa Kujawski, MD, Sanjeev Shangary, PhD, Moshe Talpaz, MD, Mark Kaminski, MD, Harry Erba, Kerby Shedden, PhD, Shaomeng Wang, PhD, Chris Saddler, BS
Journal: Blood
Blood (2007) 110 (11): 224.
https://doi.org/10.1182/blood.V110.11.224.224
Published: 2007